Ioxilan
Chemical compound
- V08AB12 (WHO)
- US: ℞-only
- Discontinued
- 1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
- 107793-72-6
N
- 3743
- DB09135
Y
- 3612
Y
- A4YJ7J11TG
- D02161
Y
- ChEMBL1201075
N
- DTXSID0048717
- Interactive image
- O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C
- InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)
Y
- Key:UUMLTINZBQPNGF-UHFFFAOYSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Ioxilan is a diagnostic contrast agent.[1] It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but was discontinued in 2017.[2]
Mechanism of action
Ioxilan is an iodinated contrast agent.[2]
References
- ^ Cheng KT (December 2007). "Ioxilan carbonate particles". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641969.
- ^ a b Oxilan FDA Professional Drug Information. Accessed 2021-04-07.
- v
- t
- e
Iodinated, Water soluble |
| ||||||
---|---|---|---|---|---|---|---|
Iodinated, Water insoluble |
| ||||||
Non-iodinated |
Paramagnetic | |
---|---|
Superparamagnetic |
|
Other |
- Microspheres of human albumin
- Microparticles of galactose
- Perflenapent
- Microspheres of phospholipids
- Sulfur hexafluoride
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e